AtriCure stock rises 20 percent on approval news

MedCity News logo

By Mary Vanac

Shares of West Chester, Ohio-based AtriCure Inc. (NASDAQ:ATRC) rose more than 20 percent Tuesday, a day after the Food & Drug Administration approved the company’s AtriClip system for sale in the United States.

AtriCure shares rose as high as $7.20, ending the day up $1.07 at $6.30. More than 1 million AtriCure shares traded hands. That’s 26 times as many shares than traded on any day in the last three months.

The keen investor interest makes sense. Chief Executive Officer David Drachman called receiving the FDA’s 510(k) clearance for his company’s system “a major product and clinical milestone.” The Cincinnati, Ohio-area company received European clearance, known as the CE Mark, to sell the device in October.

In May, during his company’s first-quarter conference call with analysts, Drachman estimated the U.S. market for the AtriClip Gillinov-Cosgrove Left Atrial Appendage Exclusion System at “approximately 185,000 patients representing a market opportunity for our AtriClip system of roughly $150 million per year."

That’s a huge opportunity, especially considering AtriCure had 2009 revenue of only $54.5 million, which was down 1 percent from $55.3 million in 2008. The company that’s barely past the development stage has yet to make an annual profit.

Yes, the system is partly named for Cleveland Clinic CEO Dr. Delos “Toby” Cosgrove, who co-invented it with colleague Dr. Marc Gillinov. The two thoracic and cardiovascular surgeons pioneered the practice of using a clip to block a thumb-sized pouch on top of the left side of the heart to cut down on blood clots that could lead to strokes for patients who have atrial fibrillation.

In fact, the Clinic chose the clip as one of its Top 10 Medical Innovations for 2010.

Another thing that makes AtriCure an attractive investment is the potential for the company’s ablation technologies to treat atrial fibrillation, an increasingly common arrhythmia that can cause heart attacks or strokes.

So far, neither drugs nor surgical procedures have offered sufferers much hope. The FDA has not approved cardiac ablation — scarring of the heart to disrupt bad electrical signals — as a treatment for atrial fibrillation. Yet, AtriCure has been at the forefront of clinical trials that might convince the federal regulator to give its approval.

AtriCure also has at least two underdog stories that make you want to root for its success. One story involves the Cleveland Clinic and its chief executive.

In 2005, the Wall Street Journal investigated the complicated relationships among the Clinic, Cosgrove, the Clinic’s venture capital fund and AtriCure, which licensed the AtriClip technology from the Clinic and got an investment from its venture fund, according to the Health Care Renewal blog.

Media reports led to the Clinic’s promise in 2006 to revamp its conflict-of-interest policy to make it more transparent about professionals’ commercial ties. Although Cosgrove has been eligible to receive royalties from sales of the AtriClip device, he has not received any, according to the Cleveland Plain Dealer. Fairly or not, AtriCure got singed by the accusations of double-dealing.

Early this year, AtriCure agreed to pay the federal government $3.76 million to settle a whistle-blower lawsuit and ensuing U.S. Department of Justice investigation that claimed the company marketed its ablation technologies as a treatment for atrial fibrillation.

The settlement included AtriCures’s assertions that the company and its employees did nothing wrong or illegal. Though AtriCure leaders believed they had good defenses against the lawsuit, litigation would have taken years and cost more than the settlement amount.

“Also, we are an emerging, growth-oriented company with a lean management structure,” Drachman told analysts in November when his company announced a tentative settlement. “The discovery and litigation process would have distracted management from focusing on profitability and growth. We believe the contemplated resolution will allow us to execute our business strategy, maintain our credit facility and move toward profitability without materially impeding our current capital or ongoing revenue opportunities.”

The whistle-blower case was filed in Texas by a former Boston Scientific employee. The lawsuit also named device-making giants Boston Scientific, St. Jude Medical and Medtronic, along with tiny companies Endoscopic Technologies and AtriCure.

Let’s be clear: the FDA has not approved cardiac ablation as a treatment for atrial fibrillation.

In recent investor presentations, however, AtriCure executives have been careful to repeat the FDA’s stance on the regulatory limits of its technologies. Maybe that wasn’t always the case. But it seems like AtriCure may have been caught up in the lawsuit largely because of its technologies and industry, not its marketing practices.

RSS From Medical Design & Outsourcing

  • GlobTek presents its latest level VI AC/DC adapter and connverter
    T-43086-WWVV-X.X-Q Model is an addition to GlobTek’s Level VI compliant GT-43086 family and represents GlobTek’s 6 Watt wall plug-in series of AC/DC adapters (power supplies and chargers) with International Interchangeable blades. GlobTek’s changeable input blade system with individual field replaceable input plugs, including: North America and Japan NEMA 1-15P, Australian, UK BS 1363, European CEE […]
  • Sanmina’s familiarity with FDA gets skin treatment product to market fast
    The medical market for cosmetic devices is booming. However, quickly launching new products to meet demand is becoming more challenging because device manufactures face increased regulatory scrutiny. To help meet regulatory requirements, aesthetic and other medical-device OEMs are partnering with electronics manufacturing services (EMS) companies that also offer expertise with the FDA filings necessary to […]
  • Fluid connectors and quick disconnects for IVD equipment from CPC
    Colder Products Company (CPC) offers thousands of tubing connectors, quick disconnects and fittings for smart fluid handling in IVD and analytical equipment. Non-spill connectors speed testing throughput by eliminating drips, preventing air inclusion and increasing operator safety. Panel mount connectors can be added to existing equipment or bottle caps to provide secure, leak-free connections. Puncture […]
  • 310 Watt desktop medical power supply meets efficiency level VI requirements
    Power Partners releases a new 310 Watt medical grade desktop power supply from their PEAMD Series of AC and DC adapters. The 310 Watt unit is packed for ideal performance inside a compact case measuring 7.8 x 4 x 2 in. with a weight of only 3 lbs. The PEAMD310 Series is approved to the latest […]
  • Saelig introduces Multiple Instrument System MIS4 universal test system
    Saelig Company has introduced the ABI Electronics’ Multiple Instrument Station MIS4, an all-in-one testing tool that provides all commonly required test instruments in one compact programmable hardware module, mounted in a compact case or installed in a PC-drive bay. Controlled by ABI’s sophisticated SYSTEM 8 Ultimate PC software with a simple yet programmable operator interface, […]
  • AssurX announces document management software update for small to mid-size companies in FDA regulated industries
    AssurX, an enterprise quality management, risk and regulatory compliance solution provider, announces the release of the latest update to their AssurX document management software. The document management solution provides a cost-effective solution for small to medium sized companies faced with streamlined operations and is fully compliant for FDA regulated industries. Ideal solution for small to […]
  • Saelig presents new Amplicon Impact-R 1100F series computer
    Saelig Company announces the Amplicon Impact-R 1100F series, a fanless system powered by the Intel ATOM D2550 processor. Configured with a high performance 2.5 in. MLC Solid State Drive (SSD), the Impact-R 1100F series is a silent controller system. With options for multiple serial communication ports, the Impact-R 1100F can offer up seven DB9 connections […]
  • Gerresheimer to acquire Centor
    Gerresheimer AG, a partner to the global pharmacy and healthcare industry, will further extend its pharmaceutical packaging business with the acquisition of Centor. Gerresheimer has reached an agreement with Nemera Development S.A. to acquire 100% of the share capital of Centor US Holding. “Centor is the highly profitable market leader for plastic vials and closures in […]
  • Methods Machine Tools presents the new Nakamura-Tome NTRX-300
    Methods Machine Tools, a developer of precision machine tools and automation, has introduced the new Nakamura-Tome NTRX-300, a multitasking turning center featuring complete parts machining in one operation, with a built-in load and unload automation system and advanced operator recognition management software. The NTRX-300 features true opposing twin spindles: an 8 in. A2-6 25 HP or […]
  • MSC Apex Diamond Python and Smart Midsurface speeds modeling to validation
    MSC Software announced a new release of MSC Apex, the company’s award-winning next generation Computer Aided Engineering (CAE) platform. The MSC Apex Diamond Python release introduces: · The fourth release of MSC Apex Modeler is a CAE Specific direct modeling and meshing solution that streamlines CAD clean-up, simplification and meshing workflow. New in this release is […]
  • Quality Metrics: FDA’s plan for a key set of measurements to help ensure manufacturers are producing quality medications
    Editor’s Note: This article is written by Ashley Boam and Mary Malarkey from the “FDA Voice” blog. Boam is an FDA’s acting Director of the Office of Policy for Pharmaceutical Quality, the Office of Pharmaceutical Quality and the Center for Drug Evaluation and Research. Malarkey is an FDA’s Director if the Office of Compliance and Biologics Quality […]

Leave a Reply